Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Revvity, Inc. (RVTY) — XLV Health Care · S&P 500 Profile |Revvity公司介紹

health-careS&P500xlv
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Revvity, Inc. (RVTY) — Business, History & S&P 500 Profile | Revvity公司介紹

Revvity, Inc. company profile · business segments · history · financial snapshot · S&P 500 rank #419 · Revvity公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Nov 4, 2026
Financials: FY2025
MARKET CAP
$18.24B
Nov 4, 2026
S&P 500 WEIGHT
0.03%
Rank #419 · Nov 4, 2026
SECTOR RANK
#50
Health Care · Nov 4, 2026
S&P 500 RANK
#419
0.03% · Nov 4, 2026

SNAPSHOT

TickerRVTY
CompanyRevvity, Inc.
GICS sector / industryHealth Care (XLV) / Life Sciences Tools & Services
S&P 500 rank (by weight)#419 · 0.03% (Nov 4, 2026)
Sector rank#50 of 60 in Health Care (Nov 4, 2026)
HeadquartersWaltham, Massachusetts
FoundedMay 9, 2023 (heritage: PerkinElmer, 1937)
CEODr. Prahlad R. Singh (President and CEO)
Employees~11,000 (as of December 28, 2025)
Market cap$18.24B (Nov 4, 2026)
SEC filingsEDGAR — CIK 0000031791

WHAT IT DOES

Revvity, Inc. is a life-sciences and diagnostics company providing instruments, reagents, software and services that help researchers discover new medicines and clinicians detect disease early, headquartered in Waltham, Massachusetts. It was created in 2023 when PerkinElmer's life-sciences and diagnostics business was renamed after the sale of its applied, food and enterprise services.

Its one-line model: sell the tools of discovery and detection — instruments plus the recurring reagents and software that run on them — into research labs and screening programmes. Fiscal 2025 total revenue was $2.86B, with operating income of $356.6M and net income of $241.2M.

The moat is installed instruments and validated assays: once a lab standardises on a platform, switching costs are high and reagent revenue recurs. Growth comes from reagents, software subscriptions and diagnostics expansion, especially newborn and infectious-disease screening.

BUSINESS SEGMENTS

Life SciencesInstruments, reagents, informatics, software, subscriptions, detection and imaging technologies enabling research breakthroughs; contract research and laboratory services. Fiscal 2025 revenue $1,431.104M.
DiagnosticsInstruments, reagents, assay platforms and software for early detection of genetic disorders, pregnancy and early-childhood screening, and infectious-disease testing. Fiscal 2025 revenue $1,424.947M.
New segment structure effective fiscal 2025 (from December 30, 2024); the older Discovery & Analytical Solutions name is superseded. Segment adjusted operating incomes sum higher than GAAP operating income because they are adjusted (non-GAAP) measures.

HISTORY

YearMilestone
1937PerkinElmer is founded (April 19, 1937) by Richard Perkin and Charles Elmer.
2021PerkinElmer acquires BioLegend for $5.25B, expanding the life-science franchise.
2022PerkinElmer agrees to divest its Applied, Food and Enterprise Services (AFES) businesses to New Mountain Capital for $2.45B total consideration.
2023AFES divestiture completes (March 13, 2023); the divested businesses keep the PerkinElmer name.
2023The remaining life-sciences and diagnostics business launches as Revvity, Inc.; NYSE ticker changes PKI to RVTY on May 16, 2023.

COMPETITIVE POSITION

  • End-to-end life-sciences tools: instruments, reagents, informatics and services that span discovery through diagnostics.
  • Diagnostics depth: newborn and infectious-disease screening franchises with long regulatory moats and recurring reagent revenue.
  • Scale after the split: the focused Revvity portfolio replaced a conglomerate structure, sharpening capital allocation on two segments.
  • Commonly recognised sector peers (not a 10-K-named list): Thermo Fisher Scientific, Danaher, Agilent Technologies and Bio-Rad Laboratories.

FINANCIAL SNAPSHOT

Total revenue$2.86B (FY2025 revenue)
Operating income$356.6M (FY2025 operating income)
Net income$241.2M (FY2025 net income)
Diluted EPS$2.07 (FY2025 diluted EPS)
Source: Revvity, Inc. fiscal 2025 Form 10-K (year ended December 28, 2025; filed February 24, 2026) and fiscal 2025 results release (February 2, 2026). Exact figures: total revenue $2,856.051M; operating income $356.64M (labelled operating income from continuing operations); net income $241.20M (SEC-derived; a ValueSense table shows $241.7M, not used); diluted EPS $2.07 (GAAP). Adjusted diluted EPS of about $5.06 is non-GAAP and is not the headline figure.

KEY RISKS

  • Research funding cycles: academic, biotech and pharma budgets drive instrument and reagent demand; funding cuts hit orders quickly.
  • Diagnostics regulation: screening products face long approvals and evolving rules on genetic and infectious-disease testing.
  • Competition from larger tools giants: Thermo Fisher and Danaher compete across both segments with greater scale.
  • China and trade exposure: a significant international business faces tariffs, export controls and local competition.

WHY IT MATTERS FOR THE S&P 500

Revvity is a small-weight health care constituent: rank #419 by weight at 0.03% as of Nov 4, 2026, and #50 in Health Care. As the renamed, focused successor to PerkinElmer's life-sciences business, it is a direct read on research-tool spending and the growth of early-disease screening.

SOURCES & METHODOLOGY

Financials, segments, headquartersRevvity, Inc. fiscal 2025 Form 10-K via SEC EDGAR and fiscal 2025 results release (see Financial Snapshot note); headquarters, CEO and history via the Form 10-K and Wikipedia company profile
Index weight & ranksSlickcharts S&P 500 weights, fetched Nov 4, 2026; sector membership per Wikipedia List of S&P 500 companies (GICS)
Market cap$18.24B (Slickcharts, Nov 4, 2026)
LogoSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics.
ChartSPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

RVTY

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

股票代號RVTY
公司Revvity, Inc.(Revvity)
GICS 板塊/行業健康護理(XLV)/生命科學工具及服務
標普500排名(按權重)#419 · 0.03%(Nov 4, 2026)
板塊內排名健康護理板塊 #50(共 60 家)(Nov 4, 2026)
總部美國麻薩諸塞州沃爾瑟姆
成立2023年5月9日(前身 PerkinElmer,1937年)
執行長Prahlad R. Singh 博士(總裁兼執行長)
員工約11,000人(截至2025年12月28日)
市值$18.24B(Nov 4, 2026)
SEC 申報EDGAR — CIK 0000031791

業務概覽

Revvity, Inc. 是生命科學與診斷公司,提供儀器、試劑、軟件與服務,協助研究人員發現新藥、臨床醫生及早檢測疾病,總部位於麻薩諸塞州沃爾瑟姆。公司於 2023 年創立,當時 PerkinElmer 在出售應用、食品及企業服務後,將餘下的生命科學與診斷業務更名。

其一句話商業模式是:向研究實驗室與篩查計劃銷售發現與檢測工具——儀器加上在其上運行的經常性試劑與軟件。2025 財年總收入 28.56 億美元,營業利潤 3.57 億美元,淨利潤 2.41 億美元。

護城河是已安裝儀器與經驗證的檢測:實驗室一旦標準化某一平台,轉換成本高昂,試劑收入經常性重複。增長來自試劑、軟件訂閱與診斷擴展,特別是新生兒與傳染病篩查。

業務板塊

生命科學令研究突破成為可能的儀器、試劑、資訊學、軟件、訂閱、檢測與成像技術;合約研究與實驗室服務。2025 財年收入 14.31104 億美元。
診斷用於早期檢測遺傳疾病、懷孕與幼兒篩查及傳染病檢測的儀器、試劑、檢測平台與軟件。2025 財年收入 14.24947 億美元。
新板塊結構自 2025 財年起生效(2024 年 12 月 30 日起);舊的 Discovery & Analytical Solutions 名稱已被取代。板塊經調整營業利潤合計高於 GAAP 營業利潤,因為屬於經調整(非 GAAP)量度。

歷史

年份里程碑
1937PerkinElmer 由 Richard Perkin 與 Charles Elmer 創立(1937 年 4 月 19 日)。
2021PerkinElmer 以 52.5 億美元收購 BioLegend,擴展生命科學業務。
2022PerkinElmer 同意以 24.5 億美元總代價向 New Mountain Capital 剝離應用、食品及企業服務(AFES)業務。
2023AFES 剝離完成(2023 年 3 月 13 日);被剝離業務保留 PerkinElmer 名稱。
2023餘下的生命科學與診斷業務以 Revvity, Inc. 推出;紐約證券交易所股票代號於 2023 年 5 月 16 日由 PKI 改為 RVTY。

競爭地位

  • 端到端生命科學工具:涵蓋發現至診斷的儀器、試劑、資訊學與服務。
  • 診斷深度:新生兒與傳染病篩查業務具長期監管護城河與經常性試劑收入。
  • 分拆後的規模:專注的 Revvity 組合取代綜合企業結構,令資本配置更集中於兩個板塊。
  • 公認的行業同業(並非 10-K 所列名單):Thermo Fisher Scientific、Danaher、Agilent Technologies 與 Bio-Rad Laboratories。

財務快照

總收入28.56 億美元(2025 財年收入)
營業利潤3.57 億美元(2025 財年營業利潤)
淨利潤2.41 億美元(2025 財年淨利潤)
稀釋 EPS2.07 美元(2025 財年稀釋 EPS)
來源:Revvity, Inc. 2025 財年 Form 10-K(截至 2025 年 12 月 28 日;2026 年 2 月 24 日申報)及 2025 財年業績公佈(2026 年 2 月 2 日)。精確數字:總收入 28.56051 億美元;營業利潤 3.5664 億美元(標示為持續經營營業利潤);淨利潤 2.412 億美元(SEC 推算;ValueSense 表格所示 2.417 億美元未予採用);稀釋 EPS 2.07 美元(GAAP)。經調整稀釋 EPS 約 5.06 美元為非 GAAP 數字,並非 headline 數字。

主要風險

  • 研究資金週期:學術、生物科技與製藥預算驅動儀器與試劑需求;資金削減會迅速打擊訂單。
  • 診斷監管:篩查產品面臨漫長審批,以及基因與傳染病檢測規則不斷演變。
  • 大型工具巨頭競爭:Thermo Fisher 與 Danaher 在兩個板塊均以更大規模競爭。
  • 中國與貿易風險:龐大的國際業務面臨關稅、出口管制與本地競爭。

對標普500的重要性

Revvity 是權重較小的健康護理成分股:按權重排名 #419,權重 0.03%(以 2026 年 11 月 4 日為準),健康護理板塊內排名 #50。作為 PerkinElmer 生命科學業務更名後的專注承繼者,它是研究工具開支與早期疾病篩查增長的直接指標。

來源與方法

財務、板塊、總部Revvity, Inc. 2025 財年 Form 10-K 數據,經 SEC EDGAR 及 2025 財年業績公佈(見財務快照附註);總部、執行長與歷史經 Form 10-K 及維基百科公司資料
指數權重與排名Slickcharts 標普 500 權重,Nov 4, 2026 抓取;板塊歸屬按維基百科標普 500 成分股名單(GICS)
市值$18.24B(Slickcharts,Nov 4, 2026)
LogoSPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。
股價圖SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

RVTY

來源:Yahoo Finance 月線(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · RVTY
Data as of Nov 4, 2026 · Financials FY2025 (10-K) · Market data Nov 2026
Previous · General Mills, Inc. (GIS) — XLP Consumer Staples · S&P 500 Profile |通用磨坊公司介紹Next · Tractor Supply Company (TSCO) — XLY Consumer Discretionary · S&P 500 Profile |Tractor Supply公司介紹

Entered 2026-11-04 02:22 · updated 2026-11-15 00:00 · rev 6